Prolonged Use of Nimotuzumab in Children with Central Nervous System Tumors: Safety and Feasibility

摘要: Abstract Primary brain tumors constitute the most frequent solid tumor of childhood. High expression epidermal growth factor receptor (EGFR) protein has been associated with progression and enhanced tumorigenicity in adult children gliomas. Nimotuzumab is a humanized antibody that targets EGFR proven efficacy To provide new therapeutic option for patients active, poor prognosis central nervous system (CNS) to evaluate feasibility safety long-term nimotuzumab therapy diverse CNS tumors, an expanded access program was launched at Juan Manuel Marquez hospital. Patients were required be 18 or younger have one tumor: low-grade glioma (LGG) high-grade (HGG), brainstem (BSG), ependymoma primitive neuroectodermal (PNET), Lansky Karnofsky performance status ≥40. Treatment consisted weekly administered 150 mg/m2 12 weeks, continuing every 1...